gvtcx

NHS Framework Agreement - North of England - Tranche B

NHS England Published 7 Oct 2019 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£514,043,196
Statuscomplete
Category (CPV) 33600000
RegionNorth East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, London, South East, South West
Deadline7 Nov 2019
Contract start1 Mar 2020
Contract end28 Feb 2022
Procedureopen
SME suitableYes
OCIDocds-b5fd17-2774d91d-05e7-400d-a217-4a5ca9db01ef

Awards (35)

This procurement was awarded to 35 suppliers. Values shown are per-award; the notice total is £514,043,196.

SupplierValueDateStatus
ACRE PHARMA LIMITED shared £205,535,556 13 Feb 2020 active
AMGEN LIMITED shared £205,535,556 13 Feb 2020 active
ASPEN PHARMA LTD shared £205,535,556 13 Feb 2020 active
ASTELLAS PHARMA LTD. shared £205,535,556 13 Feb 2020 active
BAYER PUBLIC LIMITED COMPANY shared £205,535,556 13 Feb 2020 active
BIOGEN LTD shared £205,535,556 13 Feb 2020 active
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED shared £205,535,556 13 Feb 2020 active
CELLTRION HEALTHCARE UNITED KINGDOM LIMITED shared £205,535,556 13 Feb 2020 active
DAIICHI SANKYO UK LIMITED shared £205,535,556 13 Feb 2020 active
DR. REDDY'S LABORATORIES (EU) LIMITED shared £205,535,556 13 Feb 2020 active
ELI LILLY AND COMPANY LIMITED shared £205,535,556 13 Feb 2020 active
FERRING PHARMACEUTICALS LIMITED shared £205,535,556 13 Feb 2020 active
GEDEON RICHTER (UK) LIMITED shared £205,535,556 13 Feb 2020 active
GILEAD SCIENCES LTD shared £205,535,556 13 Feb 2020 active
IPSEN LIMITED shared £205,535,556 13 Feb 2020 active
JANSSEN-CILAG LIMITED shared £205,535,556 13 Feb 2020 active
MERCK SERONO LIMITED shared £205,535,556 13 Feb 2020 active
MERCK SHARP & DOHME LIMITED shared £205,535,556 13 Feb 2020 active
MYLAN LIMITED shared £205,535,556 13 Feb 2020 active
NAPP LABORATORIES LIMITED shared £205,535,556 13 Feb 2020 active
NOVARTIS PHARMACEUTICALS UK LIMITED shared £205,535,556 13 Feb 2020 active
NOVO NORDISK LIMITED shared £205,535,556 13 Feb 2020 active
PFIZER LIMITED shared £205,535,556 13 Feb 2020 active
PHARMASURE LIMITED shared £205,535,556 13 Feb 2020 active
PROFILE PHARMA LIMITED shared £205,535,556 13 Feb 2020 active
ROCHE PRODUCTS LIMITED shared £205,535,556 13 Feb 2020 active
ROVI BIOTECH LIMITED shared £205,535,556 13 Feb 2020 active
SANDOZ LIMITED shared £205,535,556 13 Feb 2020 active
SANOFI-AVENTIS UK HOLDINGS LIMITED shared £205,535,556 13 Feb 2020 active
TAKEDA UK LIMITED shared £205,535,556 13 Feb 2020 active
TECHDOW PHARMA ENGLAND LIMITED shared £205,535,556 13 Feb 2020 active
TEVA UK LIMITED shared £205,535,556 13 Feb 2020 active
THERAMEX HQ UK LIMITED shared £205,535,556 13 Feb 2020 active
TYPHARM LIMITED shared £205,535,556 13 Feb 2020 active
UCB PHARMA LIMITED shared £205,535,556 13 Feb 2020 active

description

NHS Framework for the NHS North of England Region, Branded Medicines - Tranche B, Cytokine Modulators and other monoclonal Antibodies, and Fondaparinux

Offer reference number: CM/PHR/16/5527

CM/PHR/16/5527/01: NHS Framework for the NHS North Of England Region, Branded Medicines, Tranche B, 1 March 2020 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/16/5527/02: NHS Framework for the NHS North Of England Region, Branded Medicines Annual Tranche, Cytokine Modulators and other monoclonal antibodies, 1 March 2020 to 28 February 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/16/5527/03: NHS Framework agreement for Fondaparinux

London, 1 March 2020 to 31 August 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

South of England, 1 March 2020 to 31 August 2020 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Midlands and East, 1 March 2020 to 28 February 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
25 Mar 2020 Award (award) · 75186bcb-ea47-4cda-a461-9737cdf49bbe-351523

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.